ALS Investment Fund
Venture capital fund investing in biotech companies developing neurodegeneration drugs
About This Fund
Venture capital fund investing in biotech companies developing neurodegeneration drugs. The fund supports extraordinary people working to change the course of neurodegenerative diseases, particularly focusing on ALS. They aim to accelerate the development of a new generation of therapies that can dramatically improve the quality of life for patients by preserving cognition and motor function. The fund backs companies developing innovative drugs to transform neurodegenerative diseases into manageable conditions. This investment supports advancements in biotechnology and pharmaceutical research, with a strong emphasis on social impact by addressing a leading cause of death and disability.
Investment Focus
What They Look For
US/Europe focus; ALS/neurodegenerative disease therapies; strong founders, cutting-edge tech, platform approaches or multiple clinical drugs, proven basic science, entering clinical trials; modalities: small molecule, biologics, CRISPR, gene therapy, microbiome, protein-based, RNA therapeutics
Preparing to pitch ALS Investment Fund?
CrackTheDeck analyzes your pitch deck before the meeting — structure, narrative, investor fit.
Analyze My Deck →